Archive for the ‘Crohn’s disease’ Category

Immediate adverse events attributed to infliximab infusion by the treating gastroenterologist were infrequent (7%), and generally minor and self-limited; only one patient required discontinuation of therapy due to an anaphylactic-type infusion reaction. Similar infusion-related adverse events were seen in the data available from the retrospective clinical practice reviews from Rochester Minnesota (19%), Chicago, Illinois (6%), […]

Overall (Table 1), metronidazole and cyclosporine have a high efficacy in closing or improving fistulas, with an onset of action of a few days to a few weeks. However, neither drug provides sustained healing of fistulas, and both are rather poorly tolerated. Thalidomide shows promise in inducing closure or improvement of fistulas within weeks, but the […]

Metronidazole in a dose of 20 mg/kg, or 1000 to 1500 mg/day has been studied in three uncontrolled trials. Closure of fistulas occurred in 37%, 38% and 56% of patients, and improvement occurred in 63%, 62% and 28% of the 18, 26 and eight enrolled patients, respectively. Time to response varied from one to two […]

When the results of the retrospective Edmonton clinical practice review were compared with those reported in the randomized, placebo controlled, clinical trial with infliximab, the response rates were found to be similar (73% and 81%, respectively). Nevertheless, the complete response rate was lower in the present study than in the earlier studies (17% and 48%, […]

One hundred three of 109 patients with Crohn’s disease in our study had failed to achieve remission with corticosteroids. Initiating infliximab treatment in this corticosteroid-refractory group of patients achieved an overall clinical response rate in all disease groups of 73% (17% complete response and 55% partial response). The results of our Edmonton retrospective clinical practice […]

Our initial clinical experience with infliximab for the treatment of Crohn’s disease correlates well with the initial placebo controlled studies, as well as with three retrospective studies from the United States describing response and adverse events in clinical practice settings. Very cheap drugs at your disposal – buy mircette to get best deals at best […]

Maintenance treatment with infliximab Of the initial 80 patients who demonstrated a response to infliximab, 43 received one to eight additional infusions of infliximab to maintain response, with a median interval of eight weeks (range four to 56 weeks). Forty of the 43 patients continued to respond clinically to a second infusion of infliximab. Of […]